A clinical trial to study the effects ofhingwadi tail matrabasti and mefenamic acid in patients with dysmenorrhea
Phase 3
- Conditions
- Health Condition 1: N944- Primary dysmenorrhea
- Registration Number
- CTRI/2023/07/055239
- Lead Sponsor
- Datta Meghe Institute of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed as primary spasmodic dysmenorrhoea.
2. Patients complaining painful menstruation for first two days for two Consecutive cycles.
3. Patients having regular menstrual cycles.
Exclusion Criteria
1.Patients with major systemic diseases.
2.Patients having congenital anomalies leading to dysmenorrhea.
3.Patients having any detectable organic pelvic pathology.
4.Patients on hormonal therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome measure: change in subjective <br/ ><br>parameter like abdominal Pain during menstruation, waist-hip pain, Low backache, Duration of Pain, Nausea, Vomiting, fatigue, diarrhea, headache.Timepoint: assess after 3 consecutive menstrual cycles
- Secondary Outcome Measures
Name Time Method Secondary outcome measure: change in <br/ ><br>objective parameter VASTimepoint: assess after 3 consecutive menstrual cycles